A recent survey reveals a significant shift in Canadian eating habits and spending patterns, with approximately 3 million adults taking GLP-1 drugs like Ozempic and Mounjaro. The survey, conducted by Leger Healthcare, highlights the impact of these medications on users' lifestyles and financial decisions. Over half of the surveyed GLP-1 users reported a reduced appetite, and 40% mentioned fewer food cravings. Consequently, many are reevaluating their spending habits, with 30% opting to dine out or order takeout less frequently. Interestingly, 36% of respondents are purchasing more fresh fruits, vegetables, and protein-rich foods, indicating a conscious shift towards healthier eating. The primary motivation for taking or considering GLP-1 medications is weight loss, followed by diabetes management. However, the survey also uncovered a concerning trend: 36% of interested individuals are deterred by the cost and lack of insurance coverage, while another 36% would consider the medication if side effects were less severe. GLP-1 drugs can cause gastrointestinal issues like nausea and vomiting, and more serious complications such as gall bladder inflammation and pancreatitis. Despite these potential risks, the survey suggests that the desire for weight loss and improved health drives many Canadians to seek these medications. The survey's findings emphasize the growing popularity of GLP-1 drugs and their impact on consumer behavior, with a significant portion of Canadians taking or considering these medications for weight management and diabetes control. However, the high cost and limited insurance coverage remain significant barriers to access.
